Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akebia Therapeutics, Inc. - Common Stock (NQ:AKBA)

3.970 +0.280 (+7.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akebia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Akebia Therapeutics (NASDAQ:AKBA... 
Via Benzinga
Akebia Therapeutics Insights: Return On Capital Employed
During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. In Q4, Akebia... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Cramer Gives His Opinion On Novavax, Exact Sciences And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he prefers Moderna Inc (NASDAQ: MRNA) over Novavax, Inc. (NASDAQ: NVAX). Philip Morris International Inc. (... 
Via Benzinga
Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise
Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the... 
Via Benzinga
Looking Into Akebia Therapeutics's Return On Capital Employed
During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. Akebia... 
Via Benzinga
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Paratek Pharmaceuticals (NASDAQ:PRTK) stock increased by 12.65% to $9.26 during Tuesday's pre-market session. The company's market cap stands at $434.5... 
Via Benzinga
Akebia Therapeutics, Inc. (NASDAQ: AKBA) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA) shares over potential wrongdoing at Akebia Therapeutics, Inc was announced... 
Via SBWire
Recap: Akebia Therapeutics Q1 Earnings
Shares of Akebia Therapeutics (NASDAQ:AKBA) fell 1.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 4.26% year over... 
Via Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 39.6% to $9.23 in pre-market trading after the company disclosed updated data from its randomized, multicenter, placebo-... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback